GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hunan Er-Kang Pharmaceutical Co Ltd (SZSE:300267) » Definitions » Investments And Advances

Hunan Er-Kang Pharmaceutical Co (SZSE:300267) Investments And Advances : ¥0 Mil (As of Sep. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Hunan Er-Kang Pharmaceutical Co Investments And Advances?

Hunan Er-Kang Pharmaceutical Co's Investments And Advances for the quarter that ended in Sep. 2024 was ¥0 Mil.


Hunan Er-Kang Pharmaceutical Co Investments And Advances Historical Data

The historical data trend for Hunan Er-Kang Pharmaceutical Co's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hunan Er-Kang Pharmaceutical Co Investments And Advances Chart

Hunan Er-Kang Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Investments And Advances
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Hunan Er-Kang Pharmaceutical Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Investments And Advances Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Hunan Er-Kang Pharmaceutical Co Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.


Hunan Er-Kang Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
Kangping Road 167, National Economic and Technological Development Zone, Liuyang Changsha, Hunan, CHN, 410331
Hunan Er-Kang Pharmaceutical Co Ltd develops, produces and sells pharmaceutical products in China. The company's main products include pharmaceutical excipients and antibiotics. It offers pharmaceutical excipients, APIs and finished drug products. The pharmaceutical excipients include products such as glycerol, ethanol pharmaceutically, acceptable propylene glycol, sodium hydroxide, and pharmaceutically acceptable sugar. The company's finished drugs primarily include sulbenicillin sodium for injection and compound liquorice tablets. Its APIs include glycerin, dilute hydrochloric acid, dihydroxypropyl theophylline, sulbenicillin sodium, calamine powder, sulfadiazine, sulphaguanidine, TMP, and resorcinol. Geographically, all the activities are carried out through China.
Executives
Shuai Fang Wen Director
Wang Jun Wen Independent director
Zuo Tian Fang Independent director
Qi Yang Supervisors
Li Yi Guo Supervisors
Chen Wen Xian Supervisors
Wang Xiang Feng Directors, executives
Liu Ai Jun Directors, executives
Luo Lang Directors, executives
Fan Yi Securities Affairs Representative
Yang Hai Ming Directors, executives
Shuai You Wen Director
Shuai Rui Wen Director
Gao Zhen Ya Executives
Cao Zai Yun Director

Hunan Er-Kang Pharmaceutical Co Headlines

No Headlines